您的位置: 首页 > 农业专利 > 详情页

VECTEURS RECOMBINANTS VIRAUX ET NON VIRAUX CONTENANT LE GENE HUMAIN CODANT L'ACTIVATEUR DU PLASMINOGENE DE TYPE UROKINASE, ET LEUR UTILISATION DANS LE TRAITEMENT DE DIVERS TYPES DE FIBROSE, COMME LA FIBROSEHEPATIQUE , FIBROSE RENALE, FIBROSE PULMONAIRE, FIBROSE PANCREATIQUE ET FIBROSE CARDIAQUE, AINSI QUE DANS LE TRAITEMENT DES CICATRICES HYPERTROPHIQUES
专利权人:
TGT LABORATORIES; S.A. DE C.V.
发明人:
ARMENDARIZ BORUNDA, JUAN,AGUILAR CORDOVA, ESTUARDO
申请号:
CA2430367
公开号:
CA2430367C
申请日:
2000.11.30
申请国别(地区):
CA
年份:
2012
代理人:
摘要:
Hepatic cirrhosis is considered a severe health problemin Mexico, since it is the third mortality cause inworking-age people and there is no 100% effectivetreatment. Cirrhosis is characterized by an exacerbatedincrease of collagen in liver parenchyma, replacing thehepatocytes and thus provoking liver failure. This is oneof the reasons why we have used a gene therapy throughspecific delivery to cirrhotic livers of the gene ofhuman urokinase plasminogen activator (huPA), whichactivates mechanisms that induce the degradation ofexcess cellular matrix and stimulate hepatocyteproliferation, obtaining thus a fast re-establishment ofthe liver function. In the instant invention, themodified human uPA gene was inserted in the adenoviralvector (pAd-.DELTA.huPA), because it is not secreted and doesnot provoke hypercoagulation or spontaneous internalbleedings. Moreover, data from the bio-distribution essaywith an adenoviral vector with reporter gene .beta.-gal haveshown liver specificity as the target organ of thevector. Using ELISA, huPa protein was detected in liverhomogenates (4500 pg/ml) in animals treated withpAd--.DELTA.huPA and was also intracellularly detected throughimmunochemistry in liver cuts (80% positive cells). huPainduced a dramatic fibrosis reduction (85%) on day 10 ofvector administration, compared to control cirrhotic ratsand 55% hepatocyte proliferation increase. Liver functiontests (ALT, AST, alkaline phosphatase and bilirubin)dropped to nearly normal levels and hepatocyteproliferation was observed. Because of the two beneficialevent cascades, gene therapy with modified huPA can bedeveloped as a definite potential treatment for patientswith liver cirrhosis.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充